Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel

Journal of Ovarian Research

Volumn 5, Issue 1, 2012, Pages

  Armstrong, Stephen R ^a   Narendrula, Rashmi ^a   Guo, Baoqing ^b   Parissenti, Amadeo M ^a,b,c   McCallum, Katherine L ^c   Cull, Stephanie ^b   Lannér, Carita ^a,c  

^a LAURENTIAN UNIVERSITY   (Canada)

^b Cancer Research Laboratory   (Canada)

^c NORTHERN ONTARIO SCHOOL OF MEDICINE   (Canada)

Author keywords

A2780 cell line; Carboplatin; Docetaxel; Microarray analysis; Multidrug resistance; Ovarian cancer

Indexed keywords

ABC TRANSPORTER; ALDO KETO REDUCTASE FAMILY 1 MEMBER C3; ATP BINDING CASSETTE TRANSPORT SUBFAMILY B MEMBER 1; ATP BINDING CASSETTE TRANSPORT SUBFAMILY B MEMBER 4; CADHERIN; CADHERIN 11; CADHERIN 7; CARBOPLATIN; CELL PROTEIN; CYTOCHROME P450 1B1; DOCETAXEL; ENTEROPEPTIDASE; FIBRONECTIN LEUCINE RICH REPEAT TRANSMEMBRNE PROTEIN 3; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE 2; GLUTATHIONE TRANSFERASE OMEGA 1; LAYILIN; LEUCINE RICH GLIOMA INACTIVATED 1 PROTEIN; LIPOCORTIN 1; MEMBRANE PROTEIN; METALLOTHIONEIN II; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 9; OXIDOREDUCTASE; PRSS7 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RESISTANCE; CELL ASSAY; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GROWTH RATE; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; MICROARRAY ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

EID: 84870212259     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-5-40     Document Type: Article

References (101)

1. Cancer Statistics, 2010. Jemal A, Siegel R, Xu J, Ward E, CA Cancer J Clin 2010 60 5 277 286 10.3322/caac.20073 20610543
2. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW, Oza AM, Cancer 2007 109 4 692 702 10.1002/cncr.22466 17238181
3. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. Markman M, Trends Pharmacol Sci 2008 29 10 515 519 10.1016/j.tips.2008.07.007 18760845
4. Pharmaceutical management of ovarian cancer: current status. Markman M, Drugs 2008 68 6 771 789 10.2165/00003495-200868060-00004 18416585
5. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Ann Oncol 2005 8 16 Suppl viii12.
6. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer. Milczek T, Klasa-Mazurkiewicz D, Emerich J, Kobierski J, Acta Obstet Gynecol Scand 2009 88 4 463 467 10.1080/00016340902777525 19235559
7. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM, J Clin Oncol 2009 27 9 1419 1425 10.1200/JCO.2008.19.1684 19224846
8. A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Stordal B, Pavlakis N, Davey R, Cancer Treat Rev 2007 33 8 688 703 10.1016/j.ctrv.2007.07.013 17881133
9. Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J, Gynecol Oncol 2004 93 3 699 701 10.1016/j.ygyno.2004.03.023 15196867
10. Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cheng TC, Manorek G, Samimi G, Lin X, Berry CC, Howell SB, Cancer Chemother Pharmacol 2006 58 3 384 395 10.1007/s00280-005-0171-8 16404635
11. Molecular mechanisms of resistance and toxicity associated with platinating agents. Rabik CA, Dolan ME, Cancer Treat Rev 2007 33 1 9 23 10.1016/j.ctrv.2006.09.006 17084534
12. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP, Hamilton TC, O'Dwyer PJ, Johnson SW, Br J Cancer 2005 92 6 1149 1158 10.1038/sj.bjc.6602447 15726096
13. Genome-wide transcriptional analysis of carboplatin response in chemosensitive and chemoresistant ovarian cancer cells. Peters D, Freund J, Ochs RL, Mol Cancer Ther 2005 4 10 1605 1616 10.1158/1535-7163.MCT-04-0311 16227411
14. ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Johnatty SE, Beesley J, Paul J, Fereday S, Spurdle AB, Webb PM, Byth K, Marsh S, McLeod H, Harnett PR, Brown R, DeFazio A, Chenevix-Trench G, Clin Cancer Res 2008 14 17 5594 5601 10.1158/1078-0432.CCR-08-0606 18765553
15. Prolonged remission of platinum-refractory ovarian cancer with docetaxel: brief report and review of literature. Balat O, Kudelka AP, Edwards CL, Verschraegen CF, Kavanagh JJ, Eur J Gynaecol Oncol 1997 18 5 341 342 9378149
16. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA, Gynecol Oncol 2004 95 3 624 631 10.1016/j.ygyno.2004.08.028 15581974
17. Microtubules and resistance to tubulin-binding agents. Kavallaris M, Nat Rev Cancer 2010 10 194 204 10.1038/nrc2803 20147901
18. Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Yabuki N, Sakata K, Yamasaki T, Terashima H, Mio T, Miyazaki Y, Fujii T, Kitada K, Cancer Genet Cytogenet 2007 173 1 1 9 10.1016/j.cancergencyto.2006.07.020 17284363
19. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin- resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance. Villeneuve DJ, Hembruff SL, Veitch Z, Cecchetto M, Dew WA, Parissenti AM, Breast Cancer Res Treat 2006 96 1 17 39 10.1007/s10549-005- 9026-6 16322897
20. The Relationship between p38MAPK and Apoptosis during Paclitaxel Resistance of Ovarian Cancer Cells. Lu M, Xiao L, Li Z, Hu J, J Huazhong University of Science and Technology 2007 27 6 725 728 10.1007/s11596-007-0628-6
21. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Mozzetti S, Ferlini C, Concolino P, Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E, Ranelletti FO, Ferrandina G, Scambia G, Clin Cancer Res 2005 11 1 298 305 15671559
22. Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies. Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C, Cancer Treat Rev 2012 38 7 890 903 10.1016/j.ctrv.2012.02.011 22465195
23. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, Lai R, Voloch A, Dumontet C, Mol Cancer Ther 2005 4 12 2001 2007 10.1158/1535-7163.MCT-05-0244 16373715
24. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Zaffaroni N, Pennati M, Colella G, Perego P, Supino R, Gatti L, Pilotti S, Zunino F, Daidone MG, Cell Mol Life Sci 2002 59 8 1406 1412 10.1007/s00018-002-8518-3 12363043
25. Expression and activity of taxane-metabolizing enzymes in ovarian tumors. DeLoia JA, Zamboni WC, Jones JM, Strychor S, Kelley JL, Gallion HH, Gynecol Oncol 2008 108 2 355 360 10.1016/j.ygyno.2007.10.029 18063021
26. A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Rose PG, Blessing JA, Ball HG, Hoffman J, Warshal D, DeGeest K, Moore DH, Gynecol Oncol 2003 88 2 130 135 10.1016/S0090-8258(02)00091-4 12586591
27. Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel. Rose PG, Smrekar M, Gynecol Oncol 2003 91 2 423 425 10.1016/S0090-8258(03)00540-7 14599877
28. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB, J Natl Cancer Inst 2004 96 22 1682 1691 10.1093/jnci/djh323 15547181
29. Recurrent ovarian cancer: how important is it to treat to disease progression? Herzog TJ, Clin Cancer Res 2004 10 22 7439 7449 10.1158/1078-0432.CCR-04-0683 15569973
30. Weekly cisplatin with oral etoposide: a well-tolerated and highly effective regimen in relapsed ovarian cancer. Verborg WA, Campbell LR, Highley MS, Rankin EM, Int J Gynecol Cancer 2008 18 2 228 234 10.1111/j.1525-1438.2007. 00994.x 17511798
31. Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. Ozols RF, J Clin Oncol 2003 21 13 2451 2453 10.1200/JCO.2003.03.039 12829660
32. Second-line therapy for ovarian cancer. Markman M, Clin Adv Hematol Oncol 2008 6 6 421 422 18567987
33. Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers. Markman M, Webster K, Zanotti K, Kulp B, Peterson G, Belinson J, Gynecol Oncol 2004 95 1 109 113 10.1016/j.ygyno.2004.07.017 15385118
34. Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study. Rothenberg ML, Liu PY, Wilczynski S, Nahhas WA, Winakur GL, Jiang CS, Moinpour CM, Lyons B, Weiss GR, Essell JH, Smith HO, Markman M, Alberts DS, Gynecol Oncol 2004 95 3 506 512 10.1016/j.ygyno.2004.09.004 15581954
35. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM, J Clin Oncol 2008 26 1 76 82 10.1200/JCO.2007.12.1939 18165643
36. Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer. Jurado JM, Sanchez A, Pajares B, Perez E, Alonso L, Alba E, Clin Transl Oncol 2008 10 9 583 586 10.1007/s12094-008-0254-7 18796376
37. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Aravantinos G, Fountzilas G, Bamias A, Grimani I, Rizos S, Kalofonos HP, Skarlos DV, Economopoulos T, Kosmidis PA, Stathopoulos GP, Briasoulis E, Pectasides D, Samantas E, Timotheadou E, Papadimitriou C, Papanikolaou A, Onyenadum A, Papakostas P, Bafaloukos D, Dimopoulos MA, Eur J Cancer 2008 44 15 2169 2177 10.1016/j.ejca.2008.06.035 18691879
38. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R, J Clin Oncol 2003 21 17 3194 3200 10.1200/JCO.2003.02.153 12860964
39. Once-per-cycle pegfilgrastim in breast cancer patients treated with docetaxel/epidoxorubicin/cyclophosphamide. Montella L, Addeo R, Guarrasi R, Cennamo G, Faiola V, Capasso E, Caraglia M, Del Prete S, Eur J Cancer Care (Engl) 2010 19 2 200 204 10.1111/j.1365-2354.2008.01004.x
40. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel-ANZGOG 02-01. Tinker AV, Gebski V, Fitzharris B, Buck M, Stuart-Harris R, Beale P, Goldrick A, Rischin D, Gynecol Oncol 2007 104 3 647 653 10.1016/j.ygyno.2006.10.006 17079006
41. Cross-resistance studies of isogenic drug-resistant breast tumor cell lines support recent clinical evidence suggesting that sensitivity to paclitaxel may be strongly compromised by prior doxorubicin exposure. Guo B, Villeneuve DJ, Hembruff SL, Kirwan AF, Blais DE, Bonin M, Parissenti AM, Breast Cancer Res Treat 2004 85 1 31 51 10.1023/B:BREA.0000021046.29834.12 15039596
42. Potent killing of paclitaxel- and doxorubicin-resistant breast cancer cells by calphostin C accompanied by cytoplasmic vacuolization. Guo B, Hembruff SL, Villeneuve DJ, Kirwan AF, Parissenti AM, Breast Cancer Res Treat 2003 82 2 125 141 10.1023/B:BREA.0000003969.21267.81 14692656
43. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Chen YJ, Yuan CC, Chow KC, Wang PH, Lai CR, Yen MS, Wang LS, Gynecol Oncol 2005 97 1 110 117 10.1016/j.ygyno.2004.12.031 15790446
44. A systematic review of genes involved in the inverse resistance relationship between cisplatin and paclitaxel chemotherapy: role of BRCA1. Stordal B, Davey R, Curr Cancer Drug Targets 2009 9 3 354 365 10.2174/156800909788166592 19442054
45. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Veitch ZW, Guo B, Hembruff SL, Bewick AJ, Heibein AD, Eng J, Cull S, Maclean DA, Parissenti AM, Pharmacogenet Genomics 2009 19 6 477 488 10.1097/FPC.0b013e32832c484b 19440163
46. Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. Chen T, Li M, Zhang R, Wang H, J Cell Mol Med 2009 13 7 1358 1370 10.1111/j.1582-4934.2008.00360.x 18466355
47. In vitro modulation of doxorubicin and docetaxel antitumoral activity by methyl-beta-cyclodextrin. Grosse PY, Bressolle F, Pinguet F, Eur J Cancer 1998 34 1 168 174 10.1016/S0959-8049(97)00351-1 9624253
48. FAU regulates carboplatin resistance in ovarian cancer. Moss EL, Mourtada-Maarabouni M, Pickard MR, Redman CW, Williams GT, Genes Chromosomes Cancer 2010 49 1 70 77 10.1002/gcc.20721 19830698
49. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Qian X, LaRochelle WJ, Ara G, Wu F, Petersen KD, Thougaard A, Sehested M, Lichenstein HS, Jeffers M, Mol Cancer Ther 2006 5 8 2086 2095 10.1158/1535-7163.MCT-06-0111 16928830
50. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. Weberpals J, Garbuio K, O'Brien A, Clark-Knowles K, Doucette S, Antoniouk O, Goss G, Dimitroulakos J, Int J Cancer 2009 124 4 806 815 10.1002/ijc.23987 19035454
51. Collateral susceptibility of adriamycin-, melphalan- and cisplatin-resistant human ovarian tumor cells to bleomycin. Tsuruo T, Hamilton TC, Louie KG, Behrens BC, Young RC, Ozols RF, Jpn J Cancer Res 1986 77 9 941 945 2429947
52. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, Ozols RF, Cancer Res 1987 47 2 414 418 3539322
53. Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)- resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Bergman AM, Giaccone G, van Moorsel CJ, Mauritz R, Noordhuis P, Pinedo HM, Peters GJ, Eur J Cancer 2000 36 15 1974 1983 10.1016/S0959-8049(00)00246-X 11000580
54. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, Huang TH, Kim S, Nephew KP, BMC Med Genomics 2009 2 34 10.1186/1755-8794-2-34 19505326
55. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC, Cancer Res 1988 48 20 5713 5716 3139281
56. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA, J Clin Invest 2006 116 7 1955 1962 10.1172/JCI26532 16794736
57. Antiangiogenesis enhances intratumoral drug retention. Ma J, Chen CS, Blute T, Waxman DJ, Cancer Res 2011 71 7 2675 2685 10.1158/0008-5472.CAN-10-3242 21447737
58. Drug resistance and the solid tumor microenvironment. Tredan O, Galmarini CM, Patel K, Tannock IF, J Natl Cancer Inst 2007 99 19 1441 1454 10.1093/jnci/djm135 17895480
59. Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve. Kern W, Braess J, Friedrichsen S, Kaufmann CC, Schleyer E, Hiddemann W, J Cancer Res Clin Oncol 2001 127 1 64 68 10.1007/s004320000169 11206274
60. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Morgan RJ Jr, Doroshow JH, Synold T, Lim D, Shibata S, Margolin K, Schwarz R, Leong L, Somlo G, Twardowski P, Yen Y, Chow W, Lin P, Paz B, Chu D, Frankel P, Stalter S, Clin Cancer Res 2003 9 16 Pt 1 5896 5901 14676112
61. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Duan Z, Lamendola DE, Duan Y, Yusuf RZ, Seiden MV, Cancer Chemother Pharmacol 2005 55 3 277 285 10.1007/s00280-004-0878-y 15565326
62. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Lamendola DE, Duan Z, Yusuf RZ, Seiden MV, Cancer Res 2003 63 9 2200 2205 12727840
63. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M, Br J Cancer 1997 75 6 869 877 10.1038/bjc.1997.154 9062409
64. Mitomycin C cross-resistance induced by adriamycin in human ovarian cancer cells in vitro. Mizuno K, Furuhashi Y, Maeda O, Iwata M, Misawa T, Kawai M, Kano T, Tomoda Y, Cancer Chemother Pharmacol 1990 26 5 333 339 10.1007/BF02897288 1976451
65. Platinum-Taxol non-cross resistance in epithelial ovarian cancer. Gore ME, Preston N, A'Hern RP, Hill C, Mitchell P, Chang J, Nicolson M, Br J Cancer 1995 71 6 1308 1310 10.1038/bjc.1995.253 7779729
66. Peritoneal mesothelial hyperplasia associated with gynaecological disease: a potential diagnostic pitfall that is commonly associated with endometriosis. Oparka R, McCluggage WG, Herrington CS, J Clin Pathol 2011 64 4 313 318 10.1136/jcp.2010.086074 21421699
67. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Pineiro R, Maffucci T, Falasca M, Oncogene 2010 30 2 142 152 20838378
68. Noninvasive assessment of cell proliferation in ovarian cancer using [18F] 3'deoxy-3-fluorothymidine positron emission tomography/computed tomography imaging. Richard SD, Bencherif B, Edwards RP, Elishaev E, Krivak TC, Mountz JM, DeLoia JA, Nucl Med Biol 2011 38 4 485 491 10.1016/j.nucmedbio.2010.12.003 21531285
69. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N, Kikuchi N, Satoh H, Sakamoto T, Hizawa N, Itoh K, Yamamoto M, Clin Cancer Res 2009 15 10 3423 3432 10.1158/1078-0432.CCR-08-2822 19417020
70. Cell proliferation and drug resistance in hepatocellular carcinoma are modulated by Rho GTPase signals. Sterpetti P, Marucci L, Candelaresi C, Toksoz D, Alpini G, Ugili L, Baroni GS, Macarri G, Benedetti A, Am J Physiol Gastrointest Liver Physiol 2006 290 4 624 G632 10.1152/ajpgi.00128.2005 16322093
71. Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia. Kaaijk P, Kaspers GJ, Van Wering ER, Broekema GJ, Loonen AH, Hahlen K, Schmiegelow K, Janka-Schaub GE, Henze G, Creutzig U, Veerman AJ, Br J Cancer 2003 88 5 775 781 10.1038/sj.bjc.6600787 12618889
72. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Shain KH, Dalton WS, Mol Cancer Ther 2001 1 1 69 78 12467240
73. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y, Yamori T, Cancer Res 2002 62 4 1139 1147 11861395
74. Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells. Deng HB, Parekh HK, Chow KC, Simpkins H, J Biol Chem 2002 277 17 15035 15043 10.1074/jbc.M112028200 11842089
75. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A, Lancet Oncol 2011 12 9 852 861 10.1016/S1470-2045(11)70214-5 21862407
76. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, Shafait S, Lau A, Cranston AN, O'Connor MJ, Huntsman DG, Wang Y, Gilks CB, Clin Cancer Res 2010 17 4 783 791 21097693
77. Making the best of PARP inhibitors in ovarian cancer. Banerjee S, Kaye SB, Ashworth A, Nat Rev Clin Oncol 2010 7 9 508 519 10.1038/nrclinonc.2010.116 20700108
78. c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Pyndiah S, Tanida S, Ahmed KM, Cassimere EK, Choe C, Sakamuro D, Sci Signal 2011 4 166 a19 10.1126/scisignal.2001556 21447800
79. The Role of PARP 1 for Cisplatin-Based Chemoresistance. Yamashita T, Miyamoto S, O'Malley B, Li D, Otolaryngol Head Neck Surg 2010 143 2S2 54
80. Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin. Cheng JC, Auersperg N, Leung PC, Oncogene 2011 30 9 1020 1031 10.1038/onc.2010.486 20972462
81. Downregulation of cell surface CA125/MUC16 induces epithelial-to- mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Comamala M, Pinard M, Theriault C, Matte I, Albert A, Boivin M, Beaudin J, Piche A, Rancourt C, Br J Cancer 2011 104 6 989 999 10.1038/bjc.2011.34 21326240
82. Analysis of epithelial and mesenchymal markers in ovarian cancer reveals phenotypic heterogeneity and plasticity. Strauss R, Li ZY, Liu Y, Beyer I, Persson J, Sova P, Moller T, Pesonen S, Hemminki A, Hamerlik P, Drescher C, Urban N, Bartek J, Lieber A, PLoS One 2011 6 1 16186 10.1371/journal.pone. 0016186 21264259
83. MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. Theriault C, Pinard M, Comamala M, Migneault M, Beaudin J, Matte I, Boivin M, Piche A, Rancourt C, Gynecol Oncol 2011 121 3 434 443 10.1016/j.ygyno.2011.02.020 21421261
84. Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Green SK, Francia G, Isidoro C, Kerbel RS, Mol Cancer Ther 2004 3 2 149 159 14985455
85. N-cadherin and cadherin 11 modulate postnatal bone growth and osteoblast differentiation by distinct mechanisms. Di Benedetto A, Watkins M, Grimston S, Salazar V, Donsante C, Mbalaviele G, Radice GL, Civitelli R, J Cell Sci 2010 123 Pt 15 2640 2648 20605916
86. Epithelial to Mesenchymal Transition of a Primary Prostate Cell Line with Switches of Cell Adhesion Modules but without Malignant Transformation. Ke X-S, Qu Y, Goldfinger N, Rostad K, Hovland R, Akslen LA, Rotter V, Oyan AM, Kalland K-H, PLoS One 2008 3 10 3368 10.1371/journal.pone.0003368 18852876
87. The intracellular domain of cadherin-11 is not required for the induction of cell aggregation, adhesion or gap-junction formation. Braungart E, Hartman E, Bechler K, Hofler H, Atkinson MJ, Cell Commun Adhes 2001 8 1 15 27 10.3109/15419060109080704 11775026
88. Building the synovium: cadherin-11 mediates fibroblast-like synoviocyte cell-to-cell adhesion. Kiener HP, Brenner MB, Arthritis Res Ther 2005 7 2 49 54 10.1186/ar1495 15743489
89. Identification of three human type-II classic cadherins and frequent heterophilic interactions between different subclasses of type-II classic cadherins. Shimoyama Y, Tsujimoto G, Kitajima M, Natori M, Biochem J 2000 349 Pt 1 159 167 10861224
90. Fibroblast cell shape and adhesion in vitro is altered by overexpression of the 7a and 7b isoforms of protocadherin 7, but not the 7c isoform. Yoshida K, Cell Mol Biol Lett 2003 8 3 735 741 12949613
91. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair. Chu G, J Biol Chem 1994 269 2 787 790 8288625
92. Glutathione-associated enzymes in anticancer drug resistance. Tew KD, Cancer Res 1994 54 16 4313 4320 8044778
93. Increased expression of LGI1 gene triggers growth inhibition and apoptosis of neuroblastoma cells. Gabellini N, Masola V, Quartesan S, Oselladore B, Nobile C, Michelucci R, Curtarello M, Parolin C, Palu G, J Cell Physiol 2006 207 3 711 721 10.1002/jcp.20627 16518856
94. LGI1, a putative tumor metastasis suppressor gene, controls in vitro invasiveness and expression of matrix metalloproteinases in glioma cells through the ERK1/2 pathway. Kunapuli P, Kasyapa CS, Hawthorn L, Cowell JK, J Biol Chem 2004 279 22 23151 23157 10.1074/jbc.M314192200 15047712
95. Clinical pharmacokinetics of docetaxel. Clarke SJ, Rivory LP, Clin Pharmacokinet 1999 36 2 99 114 10.2165/00003088-199936020-00002 10092957
96. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG, Verweij J, Sparreboom A, Clin Pharmacol Ther 2004 75 5 448 454 10.1016/j.clpt.2004.01. 001 15116057
97. CYP1B1 expression is induced by docetaxel: effect on cell viability and drug resistance. Martinez VG, O'Connor R, Liang Y, Clynes M, Br J Cancer 2008 98 3 564 570 10.1038/sj.bjc.6604195 18212750
98. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel. Sissung TM, Danesi R, Price DK, Steinberg SM, de Wit R, Zahid M, Gaikwad N, Cavalieri E, Dahut WL, Sackett DL, Figg WD, Sparreboom A, Mol Cancer Ther 2008 7 1 19 26 10.1158/1535-7163.MCT-07-0557 18187806
99. Correlations between RNA and protein expression profiles in 23 human cell lines. Gry M, Rimini R, Stromberg S, Asplund A, Ponten F, Uhlen M, Nilsson P, BMC Genomics 2009 10 365 10.1186/1471-2164-10-365 19660143
100. Correlation between mRNA detected by microarrays and qRT-PCR and protein detected by immunohistochemistry of cyclins in tumour tissue from colonic adenocarcinomas. Jonsdottir K, Storkson R, Krog A, Bukholm IRK, The Open Pathol J 2008 2 96 101 10.2174/1874375700802010096
101. Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles. Shebl FM, Pinto LA, Garcia-Pineres A, Lempicki R, Williams M, Harro C, Hildesheim A, Cancer Epidemiol Biomarkers Prev 2010 19 4 978 981 10.1158/1055-9965.EPI-10-0064 20332253